Clinical trials: Schnitzler Syndrome
- Condition Schnitzler Syndrome
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Schnitzler Syndrome
A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients With Schnitzler's Syndrome
The aim of this study is to assess the effectiveness and safety of Ilaris (canakinumab) in clinical use in patients with Schnitzler's syndrome.
- Trial name
- NCT07598422
- Where
- 5 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals